nimodipine has been researched along with Nerve Degeneration in 18 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with nimodipine reduced the degeneration of dopaminergic (DA) neurons induced by LPS in mesencephalic neuron-glia cultures in a dose-dependent manner." | 5.35 | Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. ( An, L; Bao, Y; Hu, X; Li, Y; Liu, Y, 2009) |
| "Pretreatment with nimodipine reduced the degeneration of dopaminergic (DA) neurons induced by LPS in mesencephalic neuron-glia cultures in a dose-dependent manner." | 1.35 | Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. ( An, L; Bao, Y; Hu, X; Li, Y; Liu, Y, 2009) |
| "Nimodipine was administered by intragastric gavage (80 mg/kg per day) for 30 days." | 1.35 | The homeostasis of iron and suppression of HO-1 involved in the protective effects of nimodipine on neurodegeneration induced by aluminum overloading in mice. ( Guo, JZ; Yuan, Y; Zhou, QX, 2008) |
| " The animals were treated with either one of the drugs at previously defined relevant dosage or control." | 1.33 | Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine. ( Gahm, C; Holmin, S; Mathiesen, T; Rudehill, S, 2005) |
| "Nimodipine pre-treatment significantly attenuated the loss of cortical cholinergic innervation and preserved the functional integrity of cholinergic projection neurons in the magnocellular nucleus basalis." | 1.31 | Increased amyloid precursor protein expression and serotonergic sprouting following excitotoxic lesion of the rat magnocellular nucleus basalis: neuroprotection by Ca(2+) antagonist nimodipine. ( Abrahám, I; Dijkstra, IM; Harkany, T; Horvath, KM; Keijser, J; Luiten, PG; Oosterink, BJ; Van der Zee, EA, 2000) |
| "In nimodipine-treated rats the rotation behaviour after 1 week was more prominent (3." | 1.30 | Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine. ( Earl, CD; Kupsch, A; Oertel, WH; Sautter, J, 1997) |
| "Nimodipine was applied to the nutrient medium simultaneously with QUIN (both at 100 microM)." | 1.28 | Protective effect of nimodipine against quinolinic acid-induced damage of rat hippocampus in vitro. ( Kida, E; Matyja, E, 1991) |
| "Nimodipine was shown to reduce the contralateral stimulus removal time when the animals began testing two weeks after surgery, but not when testing began 1 day after surgery and overlapped the period of drug administration." | 1.28 | Sensorimotor cortical lesion effects and treatment with nimodipine. ( Andersen, AB; Andersen, CS; Finger, S; Hoagland, N, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 11 (61.11) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Hu, X | 1 |
| Liu, Y | 1 |
| Bao, Y | 1 |
| An, L | 1 |
| Sekiya, T | 1 |
| Yagihashi, A | 1 |
| Asano, K | 1 |
| Suzuki, S | 1 |
| Sobrado, M | 1 |
| López, MG | 1 |
| Carceller, F | 1 |
| García, AG | 1 |
| Roda, JM | 1 |
| Gahm, C | 1 |
| Holmin, S | 1 |
| Rudehill, S | 1 |
| Mathiesen, T | 1 |
| Yuan, Y | 1 |
| Guo, JZ | 1 |
| Zhou, QX | 1 |
| Fanelli, RJ | 1 |
| McCarthy, RT | 1 |
| Chisholm, J | 1 |
| Gispen, WH | 1 |
| Hamers, FP | 1 |
| Rami, A | 1 |
| Krieglstein, J | 1 |
| de Jonge, MC | 1 |
| Traber, J | 1 |
| Stuiver, BT | 1 |
| Douma, BR | 1 |
| Bakker, R | 1 |
| Nyakas, C | 1 |
| Luiten, PG | 2 |
| Sautter, J | 1 |
| Kupsch, A | 1 |
| Earl, CD | 1 |
| Oertel, WH | 1 |
| Corso, TD | 1 |
| Mostafa, HM | 1 |
| Collins, MA | 1 |
| Neafsey, EJ | 1 |
| Harkany, T | 1 |
| Dijkstra, IM | 1 |
| Oosterink, BJ | 1 |
| Horvath, KM | 1 |
| Abrahám, I | 1 |
| Keijser, J | 1 |
| Van der Zee, EA | 1 |
| Sheen, VL | 1 |
| Dreyer, EB | 1 |
| Macklis, JD | 1 |
| Matyja, E | 1 |
| Kida, E | 1 |
| Etienne, P | 1 |
| Hakim, A | 1 |
| Andersen, AB | 1 |
| Finger, S | 1 |
| Andersen, CS | 1 |
| Hoagland, N | 1 |
| Mossakowski, MJ | 1 |
| Gadamski, R | 1 |
3 reviews available for nimodipine and Nerve Degeneration
| Article | Year |
|---|---|
Calcium and neuronal dysfunction in peripheral nervous system.
Topics: Aging; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Cisplatin; Diabetic Neuropathie | 1994 |
Nimodipine: cognition, aging, and degeneration.
Topics: Aging; Animals; Calcium; Cognition; Homeostasis; Humans; Nerve Degeneration; Nimodipine | 1993 |
Clinical testing of compounds modifying acute and chronic neurodegeneration in the CNS.
Topics: Aged; Alzheimer Disease; Central Nervous System; Cerebrovascular Disorders; Clinical Trials as Topic | 1990 |
1 trial available for nimodipine and Nerve Degeneration
| Article | Year |
|---|---|
Clinical testing of compounds modifying acute and chronic neurodegeneration in the CNS.
Topics: Aged; Alzheimer Disease; Central Nervous System; Cerebrovascular Disorders; Clinical Trials as Topic | 1990 |
15 other studies available for nimodipine and Nerve Degeneration
| Article | Year |
|---|---|
Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.
Topics: Animals; Cell Culture Techniques; Dopamine; Inflammation; Lipopolysaccharides; Mice; Microglia; NADP | 2009 |
Nimodipine ameliorates trauma-induced cochlear neuronal death.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Signaling; Cell Death; Cochlear Nerve; Disease M | 2002 |
Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia.
Topics: Animals; Apoptosis; Brain Ischemia; Calcium Channel Blockers; Cerebral Cortex; Cerebral Infarction; | 2003 |
Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Brain; Brain Injuries; Calcium Channel Blockers; Cell | 2005 |
The homeostasis of iron and suppression of HO-1 involved in the protective effects of nimodipine on neurodegeneration induced by aluminum overloading in mice.
Topics: Aluminum; Animals; Calcium Channel Blockers; Heme Oxygenase-1; Hippocampus; Homeostasis; Immunohisto | 2008 |
Neuropharmacology of nimodipine: from single channels to behavior.
Topics: Aging; Amyloid beta-Peptides; Animals; Behavior, Animal; Calcium; Cells, Cultured; Dementia; Female; | 1994 |
Neuronal protective effects of calcium antagonists in cerebral ischemia.
Topics: Animals; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Electroenceph | 1994 |
In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection.
Topics: Aging; Analysis of Variance; Animals; Brain; Dizocilpine Maleate; Dose-Response Relationship, Drug; | 1996 |
Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine.
Topics: Animals; Behavior, Animal; Calcium Channel Blockers; Dopamine; Female; Immunohistochemistry; Injecti | 1997 |
Brain neuronal degeneration caused by episodic alcohol intoxication in rats: effects of nimodipine, 6,7-dinitro-quinoxaline-2,3-dione, and MK-801.
Topics: Alcoholic Intoxication; Animals; Brain; Calcium Channel Blockers; Dentate Gyrus; Dizocilpine Maleate | 1998 |
Increased amyloid precursor protein expression and serotonergic sprouting following excitotoxic lesion of the rat magnocellular nucleus basalis: neuroprotection by Ca(2+) antagonist nimodipine.
Topics: Amyloid beta-Protein Precursor; Animals; Axons; Basal Nucleus of Meynert; Calcium Channels, L-Type; | 2000 |
Calcium-mediated neuronal degeneration following singlet oxygen production.
Topics: Animals; Calcium; Cell Membrane; Cells, Cultured; Cerebral Cortex; Cytosol; Embryo, Mammalian; Fluor | 1992 |
Protective effect of nimodipine against quinolinic acid-induced damage of rat hippocampus in vitro.
Topics: Animals; Hippocampus; Microscopy, Electron; Models, Neurological; Nerve Degeneration; Neurons; Nimod | 1991 |
Sensorimotor cortical lesion effects and treatment with nimodipine.
Topics: Animals; Brain Mapping; Calcium; Cell Survival; Female; Mechanoreceptors; Motor Activity; Motor Cort | 1990 |
[Effect of a calcium channel blocker on the development of ischemic neuron damage in sector CA1 of the horn of Ammon in Mongolian gerbils].
Topics: Animals; Brain Ischemia; Cricetinae; Gerbillinae; Hippocampus; Male; Nerve Degeneration; Neurons; Ni | 1987 |